Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperoside is a naturally occurring flavonol glycoside, specifically the 3-O-galactoside of quercetin, with the molecular formula C21H20O12 and a molecular weight of 464.40 g/mol[4][6][8][11]. It is commonly extracted from various fruits, vegetables, and medicinal plants, and is known for its wide spectrum of biological activities, including antioxidant, anti-inflammatory, antitumor, neuroprotective, vasoprotective, and hepatoprotective effects[1][3][5][7]. Mechanistically, hyperoside exerts its effects by modulating multiple cellular signaling pathways, such as PI3K/AKT, MAPK, AMPK, NF-κB, Wnt/β-catenin, and TLR4[1][3][9]. It induces apoptosis, inhibits cell proliferation, blocks angiogenesis, and sensitizes cancer cells to chemotherapy[1][3]. Hyperoside has demonstrated therapeutic potential in preclinical models for cancer, diabetes, Alzheimer’s disease, Parkinson’s disease, pulmonary fibrosis, and liver diseases[1][3][5][7]. It is not approved as a pharmaceutical drug; it is primarily experimented with in laboratory and preclinical models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperoside.